TKL Research appoints vp of operational excellence

US CRO hires Kevin Vernarec

Kevin Vernarec has been appointed to the newly created position of vice president of operational excellence at US clinical research organisation TKL Research.

Vernarec has previously held a variety of operational roles at multinational CROs covering global project management, clinical operations, proposals, budgeting and costing, CTMS and EDC systems implementation, vendor management, process re-engineering and project planning and tracking.

Headquartered in Rochelle Park, New Jersey, TKL Research provides clinical trial management services for Phase I-IV clinical research studies, including an inpatient Phase I facility and outpatient specialised research clinics.

You may also like

Regulatory

TKL Research agrees to sell clinical trials division

TKL Research, a dermatology specialty clinical research organization (CRO), announced today that it has signed an agreement to sell its Clinical Trials Division (CTD) to QuintilesIMS.
Manufacturing

Lonza opens capsule drug development-focused site at its Colmar facility

The new addition to the French site will allow customers access to experts and technologies ideal for capsule formulation and development
Research & Development

Adenosine A2a receptor: novel biophysical fragment screening using polymer-encapsulated nanodiscs

Fragment screening is a useful method for hit identification as it offers an efficient and flexible way to identify novel therapeutic starting points that other techniques may have missed because of the small molecular size of the fragments
Research & Development

Roche's antiviral Xofluza reduces flu transmission in Phase III trial

Topline results suggest that Xofluza could be used to reduce the transmission of seasonal influenza
Research & Development

RSSL opens 3D imaging and metrology laboratory for end-to-end research and analysis

The laboratory will offer, micro-CT, microscopy and spectroscopy services for its pharmaceutical and medical device partners
Manufacturing

Ensuring cGMP compliance in cell and gene therapy manufacturing

3P discusses how companies can scale up their CGT manufacturing protocols while remaining compliant with stringent global regulations
Manufacturing

Quotient Sciences and Vasa Therapeutics announce dosing of first subjects in VS-041 novel heart failure trial

The trial is designed to evaluate the safety, tolerability, and pharmacokinetics of VS-041 in healthy volunteers
Subscribe now